Who are Brompheniramine + pseudoephedrine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fexofenadine HCl + Pseudoephedrine HCl, brompheniramine + phenylephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brompheniramine-pseudoephedrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Brompheniramine + pseudoephedrine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brompheniramine + pseudoephedrine (Brompheniramine + pseudoephedrine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihistamine + decongestant combination. Area: Allergy/Immunology.

marketed Antihistamine + decongestant combination H1 receptor (brompheniramine); alpha-1 adrenergic receptor (pseudoephedrine) Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Brompheniramine + pseudoephedrine (Brompheniramine + pseudoephedrine) — Ache Laboratorios Farmaceuticos S.A.. Brompheniramine blocks histamine H1 receptors to reduce allergic symptoms, while pseudoephedrine stimulates alpha-adrenergic receptors to constrict nasal blood vessels and relieve congestion.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Brompheniramine + pseudoephedrine TARGET	Brompheniramine + pseudoephedrine	Ache Laboratorios Farmaceuticos S.A.	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (pseudoephedrine)
Fexofenadine HCl + Pseudoephedrine HCl	Fexofenadine HCl + Pseudoephedrine HCl	Dr. Reddy's Laboratories Limited	marketed	Antihistamine + decongestant combination	H1 receptor (fexofenadine); alpha-1 adrenergic receptor (pseudoephedrine)
brompheniramine + phenylephrine	brompheniramine + phenylephrine	Ache Laboratorios Farmaceuticos S.A.	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (phenylephrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihistamine + decongestant combination class)

Ache Laboratorios Farmaceuticos S.A. · 2 drugs in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brompheniramine + pseudoephedrine — Competitive Intelligence Brief. https://druglandscape.com/ci/brompheniramine-pseudoephedrine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab